Fink D - Search Results

1

Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial.

Hovaguimian F, Braun J, Z'graggen BR, Schläpfer M, Dumrese C, Ewald C, Dedes KJ, Fink D, Rölli U, Seeberger M, Tausch C, Papassotiropoulos B, Puhan MA, Beck-Schimmer B. Hovaguimian F, et al. Among authors: fink d. Anesthesiology. 2020 Sep;133(3):548-558. doi: 10.1097/ALN.0000000000003409. Anesthesiology. 2020. PMID: 32568845 Free article. Clinical Trial.

2

[No title available]

[No authors listed] [No authors listed] PMID: 33370833

3

Clinical presentation and surgical management of invasive lobular carcinoma of the breast.

Dedes KJ, Fink D. Dedes KJ, et al. Among authors: fink d. Breast Dis. 2008-2009;30:31-7. doi: 10.3233/BD-2009-0277. Breast Dis. 2008. PMID: 19850993 Review.

4

Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.

Bringolf L, Pestalozzi B, Fink D, Dedes K. Bringolf L, et al. Among authors: fink d. Swiss Med Wkly. 2016 Dec 19;146:w14393. doi: 10.4414/smw.2016.14393. eCollection 2016. Swiss Med Wkly. 2016. PMID: 28102883 Free article.

5

[Current adjuvant endocrine treatment of breast cancer].

Dedes KJ, Gabriel N, Fink D. Dedes KJ, et al. Among authors: fink d. Gynakol Geburtshilfliche Rundsch. 2008;48(3):130-7. doi: 10.1159/000127394. Epub 2008 Jun 17. Gynakol Geburtshilfliche Rundsch. 2008. PMID: 18566529 Review. German.

6

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.

Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Samartzis EP, et al. Among authors: fink d. Oncotarget. 2014 Jul 30;5(14):5295-303. doi: 10.18632/oncotarget.2092. Oncotarget. 2014. PMID: 24979463 Free PMC article.

7

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, Szucs TD. Dedes KJ, et al. Among authors: fink d. Eur J Cancer. 2009 May;45(8):1397-406. doi: 10.1016/j.ejca.2008.12.016. Epub 2009 Jan 13. Eur J Cancer. 2009. PMID: 19147344

8

MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.

Imesch P, Dedes KJ, Furlato M, Fink D, Fedier A. Imesch P, et al. Among authors: fink d. Int J Oncol. 2009 Sep;35(3):631-40. doi: 10.3892/ijo_00000375. Int J Oncol. 2009. PMID: 19639184 Free article.

9

Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P. Samartzis EP, et al. Among authors: fink d. Mod Pathol. 2012 Jun;25(6):885-92. doi: 10.1038/modpathol.2011.217. Epub 2012 Feb 3. Mod Pathol. 2012. PMID: 22301703 Free article.

10

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Ihnenfeld Arciénega I, Imesch P, Fink D, Dedes KJ. Ihnenfeld Arciénega I, et al. Among authors: fink d. Target Oncol. 2015 Jun;10(2):297-301. doi: 10.1007/s11523-014-0350-9. Epub 2014 Dec 17. Target Oncol. 2015. PMID: 25511015 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,110 results

Search Page

Filters